Portal for patients

​Bristol-Myers Squibb Will Localize The Production Of Antitumor Dasatinib In Russia

Bristol-Myers Squibb and the group of "R-Pharm" companies signed a license agreement regarding the localization of production anticancer drug dasatinib (trade name Spraysel) in Russia.

Bristol-Myers Squibb Will Localize The Production Of Antitumor Dasatinib In Russia

Dasatinib is a drug for the treatment of adult patients with chronic myeloid leukemia that was registered in Russia in 2008.

Last autumn, it became known about the localization of another drug by Bristol-Myers Squibb, an antiretroviral drug atazanavir on Yaroslavl factlory "R-Pharm". According to Bristol-Myers Squibb CEO in Russia Soren Giza, agreement on the localization of dasatinib and atazanavir is the result of the systematic development of cooperation with the "R-Pharm" in a socially important segment of the Russian health care.

In turn, the head director of the group of "R-Pharm" companies Vassily Ignatiev said that the efforts of both producers contribute to increasing the availability of highly innovative products for Russian patients.

See also:


No comments

Application for treatment
Sex
MTEC 2019 (eng.-com)